Related Experiment Videos
Cimetidine does not correct circulating calcium and parathyroid hormone in primary hyperparathyroidism
Journal of Endocrinological Investigation
|December 1, 1983
Summary
Cimetidine, an H2-blocker, did not improve serum calcium or parathyroid hormone levels in patients with primary hyperparathyroidism. Clinical improvement was also not observed, questioning previous findings on cimetidine
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Primary hyperparathyroidism is a condition characterized by excessive parathyroid hormone production.
- Previous reports suggested potential benefits of H2-blockers like cimetidine in managing this condition.
Purpose of the Study:
- To evaluate the efficacy of cimetidine in treating primary hyperparathyroidism.
- To assess the impact of cimetidine on serum calcium and parathyroid hormone levels.
Main Methods:
- A study involving thirteen patients with primary hyperparathyroidism.
- Treatment duration of 4-8 weeks with a daily dose of 1g cimetidine.
- Monitoring of serum calcium and parathyroid hormone concentrations.
Main Results:
- Cimetidine administration showed no significant effect on serum calcium levels.
- Parathyroid hormone concentrations remained unchanged following cimetidine treatment.
- No clinical improvement was observed in any of the participating patients.
Conclusions:
- The H2-blocker cimetidine is ineffective in managing primary hyperparathyroidism.
- Current findings contradict earlier reports on the therapeutic efficacy of cimetidine.
- Further research may be needed to explore alternative treatments for primary hyperparathyroidism.